

Clinical trials of complement inhibition for acute myocardial infarction in all type of patients

TrialResults-center www.trialresultscenter.org

1 complement inhibitor

Trial	Treatments	Patients	Trials design and methods
pexelizumab vs placebo			
APEX-AMI , 2007 [NCT00091637] n=2860/2885 follow-up: 30 days	pexelizumab given as a 2-mg/kg intravenous bolus prior to PCI followed by 0.05-mg/kg per hour infusion over the subsequent 24 hours versus placebo	primary angioplasty fo high risk STEMI	Parallel groups double blind 17 countries
COMMA , 2003 n=328/315 follow-up:	pexelizumab 2.0-mg/kg bolus and 0.05-mg/kg per h infusion for 20 hours versus placebo	patients with MI	double blind
COMPLY , 2003 n=315/316 follow-up:	pexelizumab 2.0-mg/kg bolus plus 0.05 mg/kg per h for 20 hours versus placebo	patients with acute ST-segment elevation myocardial infarction receiving fibrinolysis	double blind

References

APEX-AMI, 2007:

Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van de Werf F Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. *JAMA* 2007;297:43-51 [[17200474](#)]

Buller CE, Fu Y, Mahaffey KW, Todaro TG, Adams P, Westerhout CM, White HD, van 't Hof AW, Van de Werf FJ, Wagner GS, Granger CB, Armstrong PW ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. *Circulation* 2008;118:1335-46 [[18779444](#)]

Patel MR, Worthley SG, Stebbins A, Dill T, Rademakers FE, Vellei US, Barsness GW, Van de Werf F, Hamm CW, Armstrong PW, Granger CB, Kim RJ Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial. *JACC Cardiovasc Imaging* 2010;3:52-60 [[20129531](#)] [10.1016/j.jcmg.2009.09.014](#)

COMMA, 2003:

Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, Rollins S, Todaro TG, Nicolau JC, Ruzyllo W, Armstrong PW Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. *Circulation* 2003;108:1184-90 [[12925454](#)]

COMPLY, 2003:

Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, Armstrong PW Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMplement inhibition in myocardial infarction treated with thromboLYtics (COMPLY)

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.